We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.39, marking a -6.71% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 0.52%, and the technology-centric Nasdaq increased by 0.74%.
Prior to today's trading, shares of the maker of genetic analysis technology had gained 13.74% outpaced the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. The company's upcoming EPS is projected at -$0.18, signifying a 10.00% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $36.46 million, up 1.26% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.64 per share and a revenue of $155.12 million, signifying shifts of +22.89% and +0.72%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Pacific Biosciences of California. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Pacific Biosciences of California is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 162, placing it within the bottom 35% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.39, marking a -6.71% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 0.52%, and the technology-centric Nasdaq increased by 0.74%.
Prior to today's trading, shares of the maker of genetic analysis technology had gained 13.74% outpaced the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.
The investment community will be closely monitoring the performance of Pacific Biosciences of California in its forthcoming earnings report. The company's upcoming EPS is projected at -$0.18, signifying a 10.00% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $36.46 million, up 1.26% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.64 per share and a revenue of $155.12 million, signifying shifts of +22.89% and +0.72%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Pacific Biosciences of California. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Pacific Biosciences of California is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 162, placing it within the bottom 35% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.